AzTrials
AzTrials

Condition

Solid Tumors Clinical Trials

Studies of solid tumors, matched by condition name and medical subject headings. Start with those open to enrolment.

9,870 registered studies

In numbers

Open to volunteers
2,422
Active
3,150
With results posted
1,318
All registered
9,870

Open to volunteers: recruiting, not yet recruiting or enrolling by invitation. Active adds studies under way that have stopped recruiting.

Open to volunteers

All 2,422
  • Advanced Solid Tumor

    A Study of DS-1103a Combination Therapy in Participants With Advanced Solid Tumors

    • Recruiting
    • Age: 18 years and older
    • Phase 1

    This study will evaluate the safety and efficacy of DS-1103a combination therapy in participants with advanced solid tumors.

    Trial name
    NCT05765851
    Testing
    DS-1103a, T-DXd
    Where
    15 sites in United States, Canada and 4 more
    Volunteers
    128 people
    Sponsor
    Daiichi Sankyo
    Can I take part? NCT05765851
  • Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma

    Docetaxel and SX-682 in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma, Salivary Gland Carcinoma, and Advanced Prostate Cancer

    • Recruiting
    • Age: 18 to 120 years
    • Phase 1/2

    Background: Head and neck cancers (HNCs) account for about 5% of all cancers worldwide. They grow in the mouth, throat, nasal cavity, or salivary glands. Prostate cancer is the most common cancer in men in the United States.

    Conditions
    Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma, Paranasal Sinus Neoplasms, Nasopharyngeal Carcinoma
    Trial name
    NCT07667400
    Testing
    SX-682, DTX
    Where
    United States
    Volunteers
    120 people
    Sponsor
    National Cancer Institute (NCI)
    Can I take part? NCT07667400
  • Adjustment Disorder, Anxiety Disorder

    Virtual Reality Intervention to Improve Psychological Symptom Burden for Cancer Patients Undergoing Treatment

    • Recruiting
    • Age: 18 to 90 years

    This clinical trial tests the safety, tolerability, and effectiveness of a virtual reality intervention to improve psychological symptom burden for cancer patients undergoing treatment.

    Conditions
    Adjustment Disorder, Anxiety Disorder, Depression, Hematopoietic and Lymphoid System Neoplasm
    Trial name
    NCT07221409
    Testing
    Questionnaire Administration, Virtual Reality (VR) Intervention
    Where
    United States
    Volunteers
    24 people
    Sponsor
    Mayo Clinic
    Can I take part? NCT07221409
  • Advanced Solid Tumors

    Personalized KXV01 Lentinvivo (TCR) Injection as the Therapy for Advanced Solid Tumors

    • Recruiting
    • Age: 18 to 70 years
    • Phase 1
    • Injection or infusion

    This is a single center, single arm, open-label, dose escalation, phase 1 study to evaluate the safety, tolerability and preliminary efficacy of KXV01 TCR Lentinvivo for patients with advanced solid tumors.

    Trial name
    NCT07275853
    Testing
    KXV01 TCR Lentinvivo Injection
    Where
    China
    Volunteers
    30 people
    Sponsor
    TCRx Therapeutics Co.Ltd
    Can I take part? NCT07275853
  • Colorectal Neoplasms, Gastric Neoplasms

    Obtaining Solid Tumor Tissue From People Having Biopsy or Surgery for Certain Types of Cancer

    • Recruiting
    • Age: 2 years and older
    • Observational study

    Background: Recent advances in cancer research have led to new therapies to treat the disease. It is important to continue these advances and discover new ones. To do that, researchers need tissue samples from solid tumors.

    Conditions
    Colorectal Neoplasms, Gastric Neoplasms, Cholangiocarcinoma, Bile Duct Cancer
    Trial name
    NCT01915225
    Where
    United States
    Volunteers
    1,800 people
    Sponsor
    National Cancer Institute (NCI)
    Can I take part? NCT01915225
  • TCR-T Cells, Refractory Solid Tumors

    KSX01-TCRT Injection Project in Solid Tumors

    • Recruiting
    • Age: 18 to 70 years
    • Early Phase 1
    • Injection or infusion

    1) Safety and efficacy of TCR-T cells in subjects with refractory/relapsed solid tumors. 2) The activation and proliferation of TCR-T cells in the subject, and the survival time.

    Conditions
    TCR-T Cells, Refractory Solid Tumors, Relapsed Solid Tumors
    Trial name
    NCT05811975
    Testing
    KSX01-TCRT injection
    Where
    China
    Volunteers
    50 people
    Sponsor
    TCRx Therapeutics Co.Ltd
    Can I take part? NCT05811975
  • Metastatic Malignant Solid Neoplasm, Unresectable Malignant Solid Neoplasm

    Adding Spatially Fractionated Radiation Therapy to Standard Palliative Radiation for Improving Disease-Related Symptoms in Patients With Unresectable Solid Tumors

    • Recruiting
    • Age: 15 years and older
    • Surgery or procedure

    This clinical trial evaluates whether adding spatially fractionated radiation therapy (SFRT) to standard palliative external beam radiation therapy (EBRT) improves disease-related symptoms in patients with solid tumors that…

    Conditions
    Metastatic Malignant Solid Neoplasm, Unresectable Malignant Solid Neoplasm, Unresectable Solid Tumor, Malignant Tumor
    Trial name
    NCT07856394
    Testing
    Electronic Health Record Review, External Beam Radiation Therapy, Questionnaire Administration
    Where
    2 sites in United States
    Volunteers
    100 people
    Sponsor
    Mayo Clinic
    Can I take part? NCT07856394
  • Breast Neoplasms, Colorectal Neoplasms

    A Study of LY4257496 in Participants With Cancer (OMNIRAY)

    • Recruiting
    • Age: 18 years and older
    • Phase 1

    The main purpose of this study is to evaluate safety, tolerability, and efficacy of LY4257496 alone and as part of relevant standard of care (SOC) combination therapy in participants with Gastrin-releasing Peptide Receptor…

    Conditions
    Breast Neoplasms, Colorectal Neoplasms, Prostate Neoplasm, Endometrial Neoplasms
    Trial name
    OMNIRAY (NCT07114601)
    Testing
    LY4257496, Standard of Care Anticancer Therapies, LY4257529
    Where
    33 sites in United States, Canada and 5 more
    Volunteers
    421 people
    Sponsor
    Eli Lilly and Company
    Can I take part? OMNIRAY
  • Cancer, PDAC - Pancreatic Ductal Adenocarcinoma

    A Study to Learn About Study Medicine ALTA3263 in Adults With Advanced Solid Tumors With KRAS Mutations

    • Recruiting
    • Age: 18 years and older
    • Phase 1

    The purpose of this study is to characterize the safety and tolerability of ALTA3263 in adults with advanced solid tumors with KRAS mutations.

    Conditions
    Cancer, PDAC - Pancreatic Ductal Adenocarcinoma, NSCLC (Non-small Cell Lung Cancer), CRC (Colorectal Cancer)
    Trial name
    NCT06835569
    Testing
    ALTA3263, cetuximab, mFOLFOX6
    Where
    14 sites in United States
    Volunteers
    448 people
    Sponsor
    Alterome Therapeutics, Inc.
    Can I take part? NCT06835569
  • Advanced Solid Cancer

    Personalized KXV01 TCR Lentinvivo Injection as the Therapy for Advanced Solid Tumors

    • Recruiting
    • Age: 18 to 70 years
    • Phase 1
    • Injection or infusion

    This is a single center, single arm, open-label, dose escalation, phase 1 study to evaluate the safety, tolerability and preliminary efficacy of KXV01 TCR Lentinvivo for patients with advanced solid tumors.

    Trial name
    NCT07196579
    Testing
    KXV01 TCR Lentinvivo Injection
    Where
    China
    Volunteers
    30 people
    Sponsor
    TCRx Therapeutics Co.Ltd
    Can I take part? NCT07196579

Completed, with results posted

All 849
  • Advanced Solid Tumors

    Study of AMG 256 in Adult Subjects With Advanced Solid Tumors

    • Completed
    • Age: 18 to 100 years
    • Phase 1
    • Results posted

    To evaluate the safety and tolerability of AMG 256 in adult participants and to determine the maximum tolerated dose (MTD) and/or recommended phase 2 dose (RP2D).

    Trial name
    NCT04362748
    Testing
    AMG 256
    Where
    11 sites in United States, Australia and 2 more
    Volunteers
    34 people
    Sponsor
    Amgen
    Can I take part? NCT04362748
  • Advanced Cancer, Pancreatic Cancer Metastatic

    Safety Study of Whole Body Hyperthermia for Advanced Cancer

    • Completed
    • Age: 18 to 75 years
    • Medical device
    • Results posted

    Millions of patients die of cancer every year. There are several methods to treat cancer, including surgery, chemotherapy, radiotherapy and immunotherapy. Recently, hyperthermia therapy started playing a role in cancer therapy.

    Trial name
    MATTERS (NCT04467593)
    Testing
    Whole body hyperthermia, Standard of Care (SOC) chemotherapy according to the NCCN guidelines.
    Where
    Belgium
    Volunteers
    16 people
    Sponsor
    ElmediX
    Can I take part? MATTERS
  • Solid Neoplasms

    A Study of Dazostinag as Single Agent and Dazostinag in Combination With Pembrolizumab in Adults With Advanced or Metastatic Solid Tumors

    • Completed
    • Age: 18 years and older
    • Phase 1/2
    • Results posted

    The main aim of this study is to check if people with advanced solid tumors have side effects from dazostinag, and to check how much dazostinag they can receive without getting significant side effects from it when given alone…

    Trial name
    iintune-1 (NCT04420884)
    Testing
    Dazostinag, Pembrolizumab, Platinum
    Where
    62 sites in United States, Austria and 9 more
    Volunteers
    248 people
    Sponsor
    Takeda
    Can I take part? iintune-1
  • Tumors

    Phase 1 Study of E7090 in Subjects With Solid Tumor

    • Completed
    • Age: 20 years and older
    • Phase 1
    • Results posted

    This is a Phase 1 study of E7090 in subjects with advanced solid tumors. This study will be conducted in 2 parts: 1. Part 1 will be the dose escalation portion of this study to determine the maximum tolerated dose in subjects…

    Trial name
    NCT02275910
    Testing
    E7090
    Where
    18 sites in Japan
    Volunteers
    40 people
    Sponsor
    Eisai Co., Ltd.
    Can I take part? NCT02275910
  • Hematopoietic and Lymphoid System Neoplasm, Malignant Solid Neoplasm

    Quit2Heal Smartphone App in Helping Cancer Patients Quit Smoking

    • Completed
    • Age: 18 years and older
    • Lifestyle or therapy programme
    • Results posted

    This phase III trial compares the Quit2Heal smoking cessation smartphone application (app) to the QuitGuide app in helping cancer patients quit smoking.

    Trial name
    NCT04409236
    Testing
    Quit2Heal, QuitGuide, Survey Administration
    Where
    United States
    Volunteers
    427 people
    Sponsor
    Fred Hutchinson Cancer Center
    Can I take part? NCT04409236

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in